Supplementary Table 1
A.
B.
CI simulations display synergism (CI < 1), additive effect (CI = 1), or antagonism (CI > 1) for the entire spectrum of effect levels (Fa) in the combination of NFV and BZ (right panel). CIs for experimental values (left panel) are displayed as actual Fa-CI plots in Figure 1B.
CIs for experimental values are displayed as actual Fa-CI plots in Figure 1D.
Per
cen
t su
b-G
1 D
NA
Per
cen
t ce
ll d
eath
DMSO NFV Bortezomib NFV+Bortezomib DMSO NFV Bortezomib NFV+Bortezomib
DMSONFVBortezomibZ-VAD
PARPCleaved PARP
+---
+ ++
+ + + ++ +-
-
- - - - - -- -
- -+ - + - + - +
- Z-VAD
+ Z-VAD
- Z-VAD
+ Z-VAD*
*
RPMI8226 RPMI8226
Supplementary Figure 1
H157
DR5 precursor
DR4
DR5 mature
α-Tubulin
Bcl-2
Bax
Fas
NFVDMSO
Bortezomib -
0.5 h 8 h 24 h
- + + - - + + - - + +- + - + - + - + - + - ++ - - - + - - - + - - -
Mcl-1
Actin
Supplementary Figure 2
P-Akt (S473)
Total Akt
P-Akt (T308)
P-p44/42
α-Tubulin
P-JNK (54/46 kDa)
P-p38
Total p44/42
Total p38
NFVDMSO
Bortezomib -
0.5 h 8 h 24 h
- + + - - + + - - + +- + - + - + - + - + - ++ - - - + - - - + - - -
H157
Supplementary Figure 3
P-eIF2α
ATF3
2 43 5
Vehicle NFV
GAPDH
1
Bortezomib
CHOP
C1
PARP
C2
Bip
Total-eIF2α
XBP-1s
Cleaved PARP
Caspase 3
Cleaved Caspase 3
Cleaved Caspase 3Cleaved Caspase 3
2 43 51 2 43 51 2 43 51
NFV+Bortezomib
H157 Xenograft tumor lysates
Supplementary Figure 4
A.
HSP70
Ubiqutin
2 43 5
Vehicle NFV
GAPDH
1
Bortezomib NFV+Bortezomib
C1 C2 2 43 51 2 43 51 2 43 51
H157 Xenograft tumor lysates
B.
RPMI8226 Xenograft tumor lysates
C.
ATF3
V N Bz N+BzEx
pre
ss
ion
ra
tio
to
ve
hic
le
CHOP
Ex
pre
ss
ion
ra
tio
to
ve
hic
le
V N Bz N+Bz
Supplementary Figure 5
Supplementary Figure 6